AnaCardio AB
AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. Their mission is to make the heart stronger safely by developing innovative therapies based on ground-breaking research from Karolinska Institutet. The company's lead program, AC01, is an oral ghrelin peptidomimetic small-molecule designed to improve contractility in heart failure patients without adverse effects.
Industries
Nr. of Employees
small (1-50)
AnaCardio AB
A Working Lab Innomedicum, Nanna Svartz väg 4, 171 65 Solna, Stockholm, Sweden
Patents
Products
Oral calcium‑sensitizing inotrope (small-molecule peptidomimetic)
An orally available small-molecule peptidomimetic developed to increase cardiomyocyte contractility via calcium sensitization and modulation of ghrelin-receptor signaling; advanced through preclinical studies and early-phase clinical trials.
Oral calcium‑sensitizing inotrope (small-molecule peptidomimetic)
An orally available small-molecule peptidomimetic developed to increase cardiomyocyte contractility via calcium sensitization and modulation of ghrelin-receptor signaling; advanced through preclinical studies and early-phase clinical trials.
Services
End-to-end execution of early-phase clinical trials including protocol design, site selection, trial conduct, safety monitoring, and PK/PD evaluation.
Execution of mechanistic studies including ex vivo cardiomyocyte assays, signaling pathway analysis, and biomarker identification to support translational development.
Preparation and management of regulatory applications and interactions with health authorities to enable clinical study starts across jurisdictions.
End-to-end execution of early-phase clinical trials including protocol design, site selection, trial conduct, safety monitoring, and PK/PD evaluation.
Execution of mechanistic studies including ex vivo cardiomyocyte assays, signaling pathway analysis, and biomarker identification to support translational development.
Preparation and management of regulatory applications and interactions with health authorities to enable clinical study starts across jurisdictions.
Expertise Areas
- Clinical trial management
- Cardiac pharmacology
- Pharmacokinetics and pharmacodynamics
- Preclinical cardiac physiology and mechanism-of-action research
Key Technologies
- Ghrelin receptor pathway targeting
- Calcium sensitization of cardiac sarcomeres
- Peptidomimetic small-molecule design
- Ex vivo cardiomyocyte functional assays
News & Updates
AnaCardio announced that the first patient has been successfully dosed in its GOAL-HF1 study of AC01 in patients with heart failure and reduced ejection fraction (HFrEF). The study is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of AC01 in HFrEF patients.
AnaCardio received a patent grant in Europe for its lead program AC01, a novel contractile agent for heart failure treatment.
AnaCardio completed a USD 19 million Series A extension financing round, supported by international investors, to fund further clinical development of AC01.
AnaCardio announced that the first patient has been successfully dosed in its GOAL-HF1 study of AC01 in patients with heart failure and reduced ejection fraction (HFrEF). The study is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of AC01 in HFrEF patients.
AnaCardio received a patent grant in Europe for its lead program AC01, a novel contractile agent for heart failure treatment.
AnaCardio completed a USD 19 million Series A extension financing round, supported by international investors, to fund further clinical development of AC01.